MT 300: Dihydroergotamine Mesylate Injection - POZEN

Author：

ISSN： 1174-5886

Source： Drugs in R&D, Vol.4, Iss.2, 2003-01, pp. : 133-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MT 300 POZEN: Dihydroergotamine Mesylate Injection

By Limited A.I.

Drugs in R&D, Vol. 4, Iss. 6, 2003-01 ,pp. : 376-377

Adis International

Access to resources Recommend Favorite

Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?

By Morren John A Galvez-Jimenez Nestor

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 3085-3093

Informa Healthcare

Access to resources Recommend Favorite

Complexation of dihydroergotamine mesylate with cyclodextrin derivatives: Solubility and stability in aqueous solution

By Helm H. Muller B.W. Waaler T.

European Journal of Pharmaceutical Sciences, Vol. 3, Iss. 4, 1995-08 ,pp. : 195-201

Elsevier

Access to resources Recommend Favorite

MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine

By Silberstein Stephen

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 13, 2012-09 ,pp. : 1961-1968

Informa Healthcare

Access to resources Recommend Favorite

Dihydroergotamine: role in the treatment of migraine

By Schürks Markus

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 9, 2009-09 ,pp. : 1141-1148

Informa Healthcare

Access to resources Recommend Favorite